<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01210339</url>
  </required_header>
  <id_info>
    <org_study_id>D961FC00010</org_study_id>
    <nct_id>NCT01210339</nct_id>
  </id_info>
  <brief_title>An Interaction Study to Evaluate the Effect of Esomeprazole/Acetylsalicylic Acid on the Metabolism and Effect of Clopidogrel</brief_title>
  <official_title>An Open-label, Randomized, Single-center, 2-way Cross-over Interaction Study, Evaluating the Effect of Esomeprazole 20 mg/Acetylsalicylic Acid 81 mg on the Pharmacodynamics and the Pharmacokinetics of Clopidogrel on Days 1 and 9 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess whether esomeprazole 20 mg/Acetyl Salicylic
      Acid (ASA) 81 mg affect the metabolism of clopidogrel.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of esomeprazole 20 mg/ acetylsalicylic acid 81 mg on the pharmacodynamics of clopidogrel by assessing maximal inhibition of platelet aggregation after 9 days of clopidogrel treatment relative to baseline</measure>
    <time_frame>Pharmacodynamic sampling will be done before treatment period 1.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The effect of esomeprazole 20 mg/ acetylsalicylic acid 81 mg on the pharmacodynamics of clopidogrel by assessing maximal inhibition of platelet aggregation after 9 days of clopidogrel treatment relative to baseline</measure>
    <time_frame>Pharmacodynamic sampling will be done after treatment period 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The effect of esomeprazole 20 mg/ acetylsalicylic acid 81 mg on the pharmacodynamics of clopidogrel by assessing maximal inhibition of platelet aggregation after 9 days of clopidogrel treatment relative to baseline</measure>
    <time_frame>Pharmacodynamic sampling will be done before treatment period 2.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The effect of esomeprazole 20 mg/ acetylsalicylic acid 81 mg on the pharmacodynamics of clopidogrel by assessing maximal inhibition of platelet aggregation after 9 days of clopidogrel treatment relative to baseline</measure>
    <time_frame>Pharmacodynamic sampling will be done after treatment period 2.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effect of esomeprazole 20 mg/ acetylsalicylic acid 81 mg on the pharmacokinetics of the active metabolite of clopidogrel by assessing Area Under Curve (AUC) and Cmax.after 9 days of clopidogrel treatment</measure>
    <time_frame>Pharmacokinetic sampling will be done at the end of treatment period 1 and 2 (Day 9).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The safety and tolerability of clopidogrel alone and in combination with esomeprazole/ acetylsalicylic acid</measure>
    <time_frame>Safety will be monitored continuously. Adverse events will be collected from the first administration of Investigational Product (IP) throughout the study until the follow-up visit (on average) 7-10 days after last dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A (Clopidogrel 9 days), at least 14 days wash-out, Treatment B (Clopidogrel 4 days followed by Clopidogrel + Esomeprazole/ASA 5 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment B (Clopidogrel 4 days followed by Clopidogrel + Esomeprazole/ASA 5 days), at least 14 days wash-out, Treatment A (Clopidogrel 9 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole/ASA</intervention_name>
    <description>20 mg/81 mg once daily for five days (Day 5-9)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Axanum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male (aged between 18 and 45 years inclusive) or female (aged between 18 and 55 years
             inclusive) healthy volunteers

          -  Female healthy volunteers must be of non-childbearing potential or be of childbearing
             potential, be non-lactating and have a negative pregnancy test during the pre-entry
             visit and be using 1 clinically accepted method of contraception

          -  Have a body mass index between 19 and 30 kg/m2 inclusive

          -  No clinically significant abnormal findings at the physical examination as judged by
             the investigator

        Exclusion Criteria:

          -  Any clinically significant abnormalities in laboratory screening results as judged by
             investigator

          -  Platelet count &lt;150 x 10^9/L on Day -1 or any other conditions that would increase the
             risk of bleeding

          -  Previous bone marrow transplant

          -  Any clinically important abnormalities in rhythm, conduction or morphology of resting
             ECG
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Nagy, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2010</study_first_submitted>
  <study_first_submitted_qc>September 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2010</study_first_posted>
  <last_update_submitted>October 6, 2011</last_update_submitted>
  <last_update_submitted_qc>October 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>phase 1</keyword>
  <keyword>cross-over</keyword>
  <keyword>drug-drug Interaction</keyword>
  <keyword>esomeprazole</keyword>
  <keyword>acetylsalicylic acid</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>patients with acid associated gastrointestinal symptoms</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

